Catalent Inc (CTLT) Rating Increased to Overweight at Morgan Stanley

Catalent Inc (NASDAQ:CTLT) was upgraded by investment analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a research note issued to investors on Thursday.

CTLT has been the topic of several other research reports. BidaskClub raised shares of Catalent from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Wells Fargo & Company increased their price target on shares of Catalent from $39.00 to $43.00 and gave the company an “outperform” rating in a research note on Wednesday. Bank of America Corporation reiterated a “buy” rating and issued a $45.00 price target (up from $40.00) on shares of Catalent in a research note on Wednesday. Zacks Investment Research upgraded shares of Catalent from a “sell” rating to a “buy” rating and set a $39.00 price target on the stock in a research note on Tuesday, July 4th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $45.00 price target on shares of Catalent in a research note on Tuesday, August 29th. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Catalent has a consensus rating of “Buy” and an average target price of $37.70.

Catalent (CTLT) opened at 39.19 on Thursday. The stock has a 50 day moving average of $37.19 and a 200-day moving average of $33.73. The stock has a market cap of $4.91 billion and a P/E ratio of 45.05. Catalent has a 12 month low of $21.83 and a 12 month high of $42.22.

Catalent (NASDAQ:CTLT) last issued its earnings results on Monday, August 28th. The company reported $0.65 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.57 by $0.08. The firm had revenue of $616.90 million for the quarter, compared to analysts’ expectations of $547.48 million. Catalent had a net margin of 10.02% and a return on equity of 36.29%. The firm’s revenue was up 15.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.52 earnings per share. On average, equities analysts forecast that Catalent will post $1.61 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Catalent Inc (CTLT) Rating Increased to Overweight at Morgan Stanley” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/09/21/catalent-inc-ctlt-rating-increased-to-overweight-at-morgan-stanley.html.

In other news, SVP Christine Dolan sold 745 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $34.85, for a total transaction of $25,963.25. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Institutional investors and hedge funds have recently made changes to their positions in the company. Acrospire Investment Management LLC grew its position in shares of Catalent by 72.2% during the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock worth $109,000 after acquiring an additional 1,300 shares during the last quarter. Quantbot Technologies LP grew its position in shares of Catalent by 110.7% during the second quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock worth $120,000 after acquiring an additional 1,804 shares during the last quarter. Meadow Creek Investment Management LLC grew its position in shares of Catalent by 17.7% during the first quarter. Meadow Creek Investment Management LLC now owns 4,972 shares of the company’s stock worth $141,000 after acquiring an additional 748 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Catalent by 12.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock worth $177,000 after acquiring an additional 559 shares during the last quarter. Finally, Advisor Group Inc. grew its position in shares of Catalent by 1.3% during the second quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock worth $180,000 after acquiring an additional 65 shares during the last quarter.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Analyst Recommendations for Catalent (NASDAQ:CTLT)

Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply